Document Type


Publication Date



"With the availability of the newer selective serotonin reuptake inhibitors (SSRis), concern over a 'cholinergie rebound' seemed unnecessary since these agents demonstrate little or no anticholinergic activity. However, a review of the literature indicates that there may be other withdrawal symptoms associated with discontinuation of the SSRis. The time course and, perhaps to a lesser extent, the frequency of these symptoms appear to be correlated with the elimination half-lives of the agents."


This article was originally published in California Pharmacist, volume 43, in 1996.


California Pharmacists Association



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.